{"transactions":[{"id":731649,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":36684,"kind":"person","name":"Miller-Rich Nancy","position":1,"cik":"0001735084","reported_name":"Miller-Rich Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-18T21:40:18.000Z","date":"2026-06-17","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Automatically granted pursuant to the terms of the Company's non-employee director compensation program."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests and becomes exercisable with respect to 1/3 of the total shares on June 17, 2027 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on June 17, 2029. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan)."}],"balance_after":50000,"derivative":{"exercise_price":9.42,"expiration_date":"2036-06-16","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001193125-26-276163","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1650648/000119312526276163/ownership.xml","form_type":"4"}},{"id":741351,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":36684,"kind":"person","name":"Miller-Rich Nancy","position":1,"cik":"0001735084","reported_name":"Miller-Rich Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-11T20:27:20.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":3318,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Compensation Committee of the Board of Directors of the Issuer through the applicable vesting date."}],"balance_after":3318,"derivative":{"exercise_price":1.72,"expiration_date":"2036-06-08","underlying":"Common Stock","underlying_shares":3318},"source":{"system":"sec-edgar","filing":"0001193125-26-267634","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000119312526267634/ownership.xml","form_type":"4"}},{"id":741350,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":36684,"kind":"person","name":"Miller-Rich Nancy","position":1,"cik":"0001735084","reported_name":"Miller-Rich Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-11T20:27:20.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":70000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date."}],"balance_after":70000,"derivative":{"exercise_price":1.72,"expiration_date":"2036-06-08","underlying":"Common Stock","underlying_shares":70000},"source":{"system":"sec-edgar","filing":"0001193125-26-267634","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000119312526267634/ownership.xml","form_type":"4"}},{"id":1104579,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":36684,"kind":"person","name":"Miller-Rich Nancy","position":1,"cik":"0001735084","reported_name":"Miller-Rich Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-20T20:04:06.000Z","date":"2025-06-17","kind":"grant","planned":false,"acquired":true,"shares":22500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Automatically granted pursuant to the terms of the Company's non-employee director compensation program."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests and becomes exercisable with respect to 1/3 of the total shares on June 17, 2026 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on June 17, 2028. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan)."}],"balance_after":22500,"derivative":{"exercise_price":4.15,"expiration_date":"2035-06-16","underlying":"Common Stock","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0000950170-25-088486","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1650648/000095017025088486/ownership.xml","form_type":"4"}},{"id":1113011,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":36684,"kind":"person","name":"Miller-Rich Nancy","position":1,"cik":"0001735084","reported_name":"Miller-Rich Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-12T20:30:48.000Z","date":"2025-06-10","kind":"grant","planned":false,"acquired":true,"shares":2413,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Compensation Committee of the Board of Directors of the Issuer through the applicable vesting date."}],"balance_after":2413,"derivative":{"exercise_price":2.685,"expiration_date":"2035-06-09","underlying":"Common Stock","underlying_shares":2413},"source":{"system":"sec-edgar","filing":"0000950170-25-085475","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000095017025085475/ownership.xml","form_type":"4"}},{"id":1113010,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":36684,"kind":"person","name":"Miller-Rich Nancy","position":1,"cik":"0001735084","reported_name":"Miller-Rich Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-12T20:30:48.000Z","date":"2025-06-10","kind":"grant","planned":false,"acquired":true,"shares":62728,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date."}],"balance_after":62728,"derivative":{"exercise_price":2.685,"expiration_date":"2035-06-09","underlying":"Common Stock","underlying_shares":62728},"source":{"system":"sec-edgar","filing":"0000950170-25-085475","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000095017025085475/ownership.xml","form_type":"4"}},{"id":1383447,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":36684,"kind":"person","name":"Miller-Rich Nancy","position":1,"cik":"0001735084","reported_name":"Miller-Rich Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-10-22T00:22:37.000Z","date":"2023-04-12","kind":"purchase","planned":false,"acquired":true,"shares":509,"price":10.13,"value":5156.17,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The purchases reported herein were executed under the trading discretion of an investment advisor in a managed account, without any instruction from or knowledge of the Reporting Person.  The Reporting Person only recently become aware of these transactions."}],"balance_after":922,"source":{"system":"sec-edgar","filing":"0000950170-24-116048","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000095017024116048/ownership.xml","form_type":"4"}},{"id":1383446,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":36684,"kind":"person","name":"Miller-Rich Nancy","position":1,"cik":"0001735084","reported_name":"Miller-Rich Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-10-22T00:22:37.000Z","date":"2021-05-03","kind":"purchase","planned":false,"acquired":true,"shares":413,"price":12.81,"value":5290.53,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The purchases reported herein were executed under the trading discretion of an investment advisor in a managed account, without any instruction from or knowledge of the Reporting Person.  The Reporting Person only recently become aware of these transactions."}],"balance_after":413,"source":{"system":"sec-edgar","filing":"0000950170-24-116048","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000095017024116048/ownership.xml","form_type":"4"}},{"id":1488146,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":36684,"kind":"person","name":"Miller-Rich Nancy","position":1,"cik":"0001735084","reported_name":"Miller-Rich Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-06T20:12:28.000Z","date":"2024-06-04","kind":"grant","planned":false,"acquired":true,"shares":1736,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Compensation Committee of the Board of Directors of the Issuer through the applicable vesting date."}],"balance_after":1736,"derivative":{"exercise_price":4.09,"expiration_date":"2034-06-03","underlying":"Common Stock","underlying_shares":1736},"source":{"system":"sec-edgar","filing":"0000950170-24-069887","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000095017024069887/ownership.xml","form_type":"4"}},{"id":1488145,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":36684,"kind":"person","name":"Miller-Rich Nancy","position":1,"cik":"0001735084","reported_name":"Miller-Rich Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-06T20:12:28.000Z","date":"2024-06-04","kind":"grant","planned":false,"acquired":true,"shares":40282,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date."}],"balance_after":40282,"derivative":{"exercise_price":4.09,"expiration_date":"2034-06-03","underlying":"Common Stock","underlying_shares":40282},"source":{"system":"sec-edgar","filing":"0000950170-24-069887","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000095017024069887/ownership.xml","form_type":"4"}},{"id":1503219,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":36684,"kind":"person","name":"Miller-Rich Nancy","position":1,"cik":"0001735084","reported_name":"Miller-Rich Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right To Buy)","published_at":"2024-05-23T23:12:00.000Z","date":"2024-05-21","kind":"grant","planned":false,"acquired":true,"shares":22500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Automatically granted pursuant to the terms of the Company's non-employee director compensation program."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests and becomes exercisable with respect to 1/3 of the total shares on May 21, 2025 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on May 21, 2027. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan)."}],"balance_after":22500,"derivative":{"exercise_price":25.15,"expiration_date":"2034-05-20","underlying":"Common Stock","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0000950170-24-064211","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1650648/000095017024064211/ownership.xml","form_type":"4"}},{"id":1743637,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":36684,"kind":"person","name":"Miller-Rich Nancy","position":1,"cik":"0001735084","reported_name":"Miller-Rich Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2023-11-13T14:44:09.000Z","date":"2023-11-08","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2966,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the\nEffective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in\nrespect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the\nEffective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in\nrespect thereof."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the\nEffective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in\nrespect thereof."}],"balance_after":0,"derivative":{"exercise_price":72.74,"underlying":"Common Stock","underlying_shares":2966},"source":{"system":"sec-edgar","filing":"0001104659-23-117105","document":"tm2330435-14_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465923117105/tm2330435-14_4seq1.xml","form_type":"4"}},{"id":1743636,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":36684,"kind":"person","name":"Miller-Rich Nancy","position":1,"cik":"0001735084","reported_name":"Miller-Rich Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2023-11-13T14:44:09.000Z","date":"2023-11-08","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2174,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the\nEffective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in\nrespect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the\nEffective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in\nrespect thereof."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the\nEffective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in\nrespect thereof."}],"balance_after":0,"derivative":{"exercise_price":82.25,"underlying":"Common Stock","underlying_shares":2174},"source":{"system":"sec-edgar","filing":"0001104659-23-117105","document":"tm2330435-14_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465923117105/tm2330435-14_4seq1.xml","form_type":"4"}},{"id":1743635,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":36684,"kind":"person","name":"Miller-Rich Nancy","position":1,"cik":"0001735084","reported_name":"Miller-Rich Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2023-11-13T14:44:09.000Z","date":"2023-11-08","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":7684,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the\nEffective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in\nrespect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the\nEffective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in\nrespect thereof."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the\nEffective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in\nrespect thereof."}],"balance_after":0,"derivative":{"exercise_price":85.12,"underlying":"Common Stock","underlying_shares":7684},"source":{"system":"sec-edgar","filing":"0001104659-23-117105","document":"tm2330435-14_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465923117105/tm2330435-14_4seq1.xml","form_type":"4"}},{"id":1743634,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":36684,"kind":"person","name":"Miller-Rich Nancy","position":1,"cik":"0001735084","reported_name":"Miller-Rich Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2023-11-13T14:44:09.000Z","date":"2023-11-08","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":12547,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the\nEffective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash\npayment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of\nCompany Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the\nEffective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the\nEffective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash\npayment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of\nCompany Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the\nEffective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the\nEffective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash\npayment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of\nCompany Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the\nEffective Time."}],"balance_after":0,"derivative":{"exercise_price":9.17,"underlying":"Common Stock","underlying_shares":12547},"source":{"system":"sec-edgar","filing":"0001104659-23-117105","document":"tm2330435-14_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465923117105/tm2330435-14_4seq1.xml","form_type":"4"}},{"id":1743633,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":36684,"kind":"person","name":"Miller-Rich Nancy","position":1,"cik":"0001735084","reported_name":"Miller-Rich Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2023-11-13T14:44:09.000Z","date":"2023-11-08","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":12790,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the\nEffective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash\npayment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of\nCompany Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the\nEffective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the\nEffective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash\npayment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of\nCompany Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the\nEffective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the\nEffective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash\npayment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of\nCompany Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the\nEffective Time."}],"balance_after":0,"derivative":{"exercise_price":16.82,"underlying":"Common Stock","underlying_shares":12790},"source":{"system":"sec-edgar","filing":"0001104659-23-117105","document":"tm2330435-14_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465923117105/tm2330435-14_4seq1.xml","form_type":"4"}},{"id":1743632,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":36684,"kind":"person","name":"Miller-Rich Nancy","position":1,"cik":"0001735084","reported_name":"Miller-Rich Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2023-11-13T14:44:09.000Z","date":"2023-11-08","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":12089,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the\nEffective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash\npayment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of\nCompany Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the\nEffective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the\nEffective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash\npayment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of\nCompany Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the\nEffective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the\nEffective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash\npayment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of\nCompany Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the\nEffective Time."}],"balance_after":0,"derivative":{"exercise_price":17.08,"underlying":"Common Stock","underlying_shares":12089},"source":{"system":"sec-edgar","filing":"0001104659-23-117105","document":"tm2330435-14_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465923117105/tm2330435-14_4seq1.xml","form_type":"4"}},{"id":1743631,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":36684,"kind":"person","name":"Miller-Rich Nancy","position":1,"cik":"0001735084","reported_name":"Miller-Rich Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-11-13T14:44:09.000Z","date":"2023-11-08","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":8111,"price":19,"value":154109.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents restricted stock units (\"RSUs\") granted to the Reporting Person. Each RSU represented a contingent right to receive one share of Company Common Stock\nupon vesting of the RSU."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each RSU that was outstanding as of immediately prior to the Effective Time was cancelled and converted into\nthe contingent right to receive a cash payment (without interest and subject to any applicable tax withholding) equal to (A) the Offer Price, multiplied by (B) the number of\nshares of Company Common Stock subject to such RSU. Such payment right will vest and become payable in accordance with vesting schedule (including any vesting\nacceleration provisions) that applied to the corresponding portion of the applicable RSUs immediately prior to the Effective Time."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-23-117105","document":"tm2330435-14_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465923117105/tm2330435-14_4seq1.xml","form_type":"4"}},{"id":1743630,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":36684,"kind":"person","name":"Miller-Rich Nancy","position":1,"cik":"0001735084","reported_name":"Miller-Rich Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-11-13T14:44:09.000Z","date":"2023-11-08","kind":"other","planned":false,"acquired":false,"shares":22304,"price":19,"value":423776.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of September 26, 2023, among\nthe Issuer, Alfasigma S.p.A. (\"Alfasigma\"), and Interstellar Acquisition Inc., a wholly owned subsidiary of Alfasigma (\"Purchaser\"), pursuant to which Purchaser\ncompleted a tender offer for shares of common stock of the Issuer (\"Company Common Stock\") and thereafter merged with and into the Issuer, effective as of November 8,\n2023 (the \"Effective Time\"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right to receive\n$19.00 in cash (the \"Offer Price\") without interest and subject to applicable withholding taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-23-117105","document":"tm2330435-14_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465923117105/tm2330435-14_4seq1.xml","form_type":"4"}},{"id":1835431,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":36684,"kind":"person","name":"Miller-Rich Nancy","position":1,"cik":"0001735084","reported_name":"Miller-Rich Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-07-05T21:42:39.000Z","date":"2023-06-30","kind":"grant","planned":false,"acquired":true,"shares":915,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Compensation Committee of the Board of Directors of the Issuer through the applicable vesting date."}],"balance_after":915,"derivative":{"exercise_price":8.39,"expiration_date":"2033-06-29","underlying":"Common Stock","underlying_shares":915},"source":{"system":"sec-edgar","filing":"0000950170-23-031786","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000095017023031786/ownership.xml","form_type":"4"}},{"id":1835430,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":36684,"kind":"person","name":"Miller-Rich Nancy","position":1,"cik":"0001735084","reported_name":"Miller-Rich Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-07-05T21:42:39.000Z","date":"2023-06-30","kind":"grant","planned":false,"acquired":true,"shares":21222,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date."}],"balance_after":21222,"derivative":{"exercise_price":8.39,"expiration_date":"2033-06-29","underlying":"Common Stock","underlying_shares":21222},"source":{"system":"sec-edgar","filing":"0000950170-23-031786","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000095017023031786/ownership.xml","form_type":"4"}},{"id":1877643,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":36684,"kind":"person","name":"Miller-Rich Nancy","position":1,"cik":"0001735084","reported_name":"Miller-Rich Nancy","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-25T23:37:06.000Z","date":"2023-05-23","kind":"grant","planned":false,"acquired":true,"shares":22500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Automatically granted pursuant to the terms of the Company's non-employee director compensation program."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests and becomes exercisable with respect to 1/3 of the total shares on May 23, 2024 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on May 23, 2026. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan)."}],"balance_after":22500,"derivative":{"exercise_price":17.98,"expiration_date":"2033-05-22","underlying":"Common Stock","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0001610717-23-000071","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1650648/000161071723000071/form4.xml","form_type":"4"}},{"id":1877846,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":36684,"kind":"person","name":"Miller-Rich Nancy","position":1,"cik":"0001735084","reported_name":"Miller-Rich Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to  Purchase Common Stock","published_at":"2023-05-25T20:38:05.000Z","date":"2023-05-24","kind":"grant","planned":false,"acquired":true,"shares":12547,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"All of the options subject to the award shall vest and become exercisable on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2024 Annual Meeting of Stockholders."}],"balance_after":12547,"derivative":{"exercise_price":9.17,"expiration_date":"2033-05-24","underlying":"Common Stock","underlying_shares":12547},"source":{"system":"sec-edgar","filing":"0001104659-23-064840","document":"tm2317083-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465923064840/tm2317083-3_4seq1.xml","form_type":"4"}},{"id":1877845,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":36684,"kind":"person","name":"Miller-Rich Nancy","position":1,"cik":"0001735084","reported_name":"Miller-Rich Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-25T20:38:05.000Z","date":"2023-05-24","kind":"grant","planned":false,"acquired":true,"shares":8111,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. All of the shares subject to the award shall vest on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2024 Annual Meeting of Stockholders."}],"balance_after":30415,"source":{"system":"sec-edgar","filing":"0001104659-23-064840","document":"tm2317083-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465923064840/tm2317083-3_4seq1.xml","form_type":"4"}},{"id":2237413,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":36684,"kind":"person","name":"Miller-Rich Nancy","position":1,"cik":"0001735084","reported_name":"Miller-Rich Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-09T21:07:13.000Z","date":"2022-06-07","kind":"grant","acquired":true,"shares":2319,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Compensation Committee of the Board of Directors of the Issuer through the applicable vesting date."}],"balance_after":2319,"derivative":{"exercise_price":3.6,"expiration_date":"2032-06-06","underlying":"Common Stock","underlying_shares":2319},"source":{"system":"sec-edgar","filing":"0000899243-22-021637","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000089924322021637/doc4.xml","form_type":"4"}},{"id":2237412,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":36684,"kind":"person","name":"Miller-Rich Nancy","position":1,"cik":"0001735084","reported_name":"Miller-Rich Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-09T21:07:13.000Z","date":"2022-06-07","kind":"grant","acquired":true,"shares":53812,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date."}],"balance_after":53812,"derivative":{"exercise_price":3.6,"expiration_date":"2032-06-06","underlying":"Common Stock","underlying_shares":53812},"source":{"system":"sec-edgar","filing":"0000899243-22-021637","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000089924322021637/doc4.xml","form_type":"4"}},{"id":2253048,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":36684,"kind":"person","name":"Miller-Rich Nancy","position":1,"cik":"0001735084","reported_name":"Miller-Rich Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2022-05-27T16:17:19.000Z","date":"2022-05-25","kind":"grant","acquired":true,"shares":12790,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"All of the options subject to the award shall vest and become exercisable on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2023 Annual Meeting of Stockholders."}],"balance_after":12790,"derivative":{"exercise_price":16.82,"expiration_date":"2032-05-25","underlying":"Common Stock","underlying_shares":12790},"source":{"system":"sec-edgar","filing":"0001104659-22-065906","document":"tm2217184-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465922065906/tm2217184-3_4seq1.xml","form_type":"4"}},{"id":2253047,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":36684,"kind":"person","name":"Miller-Rich Nancy","position":1,"cik":"0001735084","reported_name":"Miller-Rich Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-05-27T16:17:19.000Z","date":"2022-05-25","kind":"grant","acquired":true,"shares":7737,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. All of the shares subject to the award shall vest on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2023 Annual Meeting of Stockholders."}],"balance_after":22304,"source":{"system":"sec-edgar","filing":"0001104659-22-065906","document":"tm2217184-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465922065906/tm2217184-3_4seq1.xml","form_type":"4"}},{"id":2256401,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":36684,"kind":"person","name":"Miller-Rich Nancy","position":1,"cik":"0001735084","reported_name":"Miller-Rich Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-25T23:02:11.000Z","date":"2022-05-23","kind":"grant","acquired":true,"shares":22500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Automatically granted pursuant to the terms of the Company's non-employee director compensation program."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests and becomes exercisable with respect to 1/3 of the total shares on May 23, 2023 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on May 23, 2025. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan)."}],"balance_after":22500,"derivative":{"exercise_price":7.77,"expiration_date":"2032-05-22","underlying":"Common Stock","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0001567619-22-011720","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1650648/000156761922011720/doc1.xml","form_type":"4"}},{"id":2519092,"issuer":{"id":133686,"kind":"organization","name":"Kadmon Holdings, Inc.","symbol":"KDMN"},"owners":[{"id":36684,"kind":"person","name":"Miller-Rich Nancy","position":1,"cik":"0001735084","reported_name":"Miller-Rich Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-11-09T17:38:51.000Z","date":"2021-11-09","kind":"disposition_to_issuer","acquired":false,"shares":96975,"price":5.92,"value":574092.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the payment per share of Common Stock received in exchange for the cancellation of each Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"In connection with the acquisition by Sanofi of the entire issued share capital of Issuer on November 9, 2021 by means of a plan of merger, all unvested stock options (\"Options\") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option."}],"balance_after":0,"derivative":{"exercise_price":3.58,"expiration_date":"2031-05-12","underlying":"Common Stock, par value $0.001","underlying_shares":96975},"source":{"system":"sec-edgar","filing":"0001104659-21-136405","document":"tm2131118-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557142/000110465921136405/tm2131118-6_4seq1.xml","form_type":"4"}},{"id":2519091,"issuer":{"id":133686,"kind":"organization","name":"Kadmon Holdings, Inc.","symbol":"KDMN"},"owners":[{"id":36684,"kind":"person","name":"Miller-Rich Nancy","position":1,"cik":"0001735084","reported_name":"Miller-Rich Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-11-09T17:38:51.000Z","date":"2021-11-09","kind":"disposition_to_issuer","acquired":false,"shares":36364,"price":5.33,"value":193820.12,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the payment per share of Common Stock received in exchange for the cancellation of each Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"In connection with the acquisition by Sanofi of the entire issued share capital of Issuer on November 9, 2021 by means of a plan of merger, all unvested stock options (\"Options\") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option."}],"balance_after":0,"derivative":{"exercise_price":4.17,"expiration_date":"2030-08-13","underlying":"Common Stock, par value $0.001","underlying_shares":36364},"source":{"system":"sec-edgar","filing":"0001104659-21-136405","document":"tm2131118-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557142/000110465921136405/tm2131118-6_4seq1.xml","form_type":"4"}},{"id":2673546,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":36684,"kind":"person","name":"Miller-Rich Nancy","position":1,"cik":"0001735084","reported_name":"Miller-Rich Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-10T21:46:01.000Z","date":"2021-06-08","kind":"grant","acquired":true,"shares":583,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Compensation Committee of the Board of Directors of the Issuer through the applicable vesting date."}],"balance_after":583,"derivative":{"exercise_price":12.97,"expiration_date":"2031-06-07","underlying":"Common Stock","underlying_shares":583},"source":{"system":"sec-edgar","filing":"0000899243-21-023011","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000089924321023011/doc4.xml","form_type":"4"}},{"id":2673545,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":36684,"kind":"person","name":"Miller-Rich Nancy","position":1,"cik":"0001735084","reported_name":"Miller-Rich Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-10T21:46:01.000Z","date":"2021-06-08","kind":"grant","acquired":true,"shares":13534,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date."}],"balance_after":13534,"derivative":{"exercise_price":12.97,"expiration_date":"2031-06-07","underlying":"Common Stock","underlying_shares":13534},"source":{"system":"sec-edgar","filing":"0000899243-21-023011","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000089924321023011/doc4.xml","form_type":"4"}},{"id":2688735,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":36684,"kind":"person","name":"Miller-Rich Nancy","position":1,"cik":"0001735084","reported_name":"Miller-Rich Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2021-06-01T19:02:38.000Z","date":"2021-05-27","kind":"grant","acquired":true,"shares":12089,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"All of the options subject to the award shall vest and become exercisable on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2022 Annual Meeting of Stockholders."}],"balance_after":12089,"derivative":{"exercise_price":17.08,"expiration_date":"2031-05-27","underlying":"Common Stock","underlying_shares":12089},"source":{"system":"sec-edgar","filing":"0001104659-21-075220","document":"tm2118118-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465921075220/tm2118118-7_4seq1.xml","form_type":"4"}},{"id":2688734,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":36684,"kind":"person","name":"Miller-Rich Nancy","position":1,"cik":"0001735084","reported_name":"Miller-Rich Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-01T19:02:38.000Z","date":"2021-05-27","kind":"grant","acquired":true,"shares":7029,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. All of the shares subject to the award shall vest on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2022 Annual Meeting of Stockholders."}],"balance_after":14567,"source":{"system":"sec-edgar","filing":"0001104659-21-075220","document":"tm2118118-7_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465921075220/tm2118118-7_4seq1.xml","form_type":"4"}},{"id":2704792,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":36684,"kind":"person","name":"Miller-Rich Nancy","position":1,"cik":"0001735084","reported_name":"Miller-Rich Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-05-20T00:32:11.000Z","date":"2021-05-17","kind":"grant","acquired":true,"shares":22500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Automatically granted pursuant to the terms of the Company's non-employee director compensation program."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests and becomes exercisable with respect to 1/3 of the total shares on May 17, 2022 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on May 17, 2024. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan)."}],"balance_after":22500,"derivative":{"exercise_price":26.89,"expiration_date":"2031-05-16","underlying":"Common Stock","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0001567619-21-010747","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1650648/000156761921010747/doc1.xml","form_type":"4"}},{"id":2714014,"issuer":{"id":133686,"kind":"organization","name":"Kadmon Holdings, Inc.","symbol":"KDMN"},"owners":[{"id":36684,"kind":"person","name":"Miller-Rich Nancy","position":1,"cik":"0001735084","reported_name":"Miller-Rich Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-05-13T16:16:18.000Z","date":"2021-05-12","kind":"grant","acquired":true,"shares":96975,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in full on the first anniversary of the grant date, or May 12, 2022"}],"balance_after":96975,"derivative":{"exercise_price":3.58,"expiration_date":"2031-05-12","underlying":"Common stock","underlying_shares":96975},"source":{"system":"sec-edgar","filing":"0001593968-21-001314","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557142/000159396821001314/primary_01.xml","form_type":"4"}},{"id":3058312,"issuer":{"id":133686,"kind":"organization","name":"Kadmon Holdings, Inc.","symbol":"KDMN"},"owners":[{"id":36684,"kind":"person","name":"Miller-Rich Nancy","position":1,"cik":"0001735084","reported_name":"Miller-Rich Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-08-13T17:19:42.000Z","date":"2020-08-13","kind":"grant","acquired":true,"shares":36364,"price":4.17,"value":151637.88,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable in three equal annual installments over 3 years from August 13, 2020, the date of grant."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Only represents derivative securities of this class."}],"balance_after":36364,"derivative":{"exercise_price":4.17,"expiration_date":"2030-08-13","underlying":"Common stock, $0.001 par value","underlying_shares":36364},"source":{"system":"sec-edgar","filing":"0001593968-20-001745","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557142/000159396820001745/primary_01.xml","form_type":"4"}},{"id":3113077,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":36684,"kind":"person","name":"Miller-Rich Nancy","position":1,"cik":"0001735084","reported_name":"Miller-Rich Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-11T21:48:39.000Z","date":"2020-06-09","kind":"grant","acquired":true,"shares":26503,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date."}],"balance_after":26503,"derivative":{"exercise_price":5.02,"expiration_date":"2030-06-08","underlying":"Common Stock","underlying_shares":26503},"source":{"system":"sec-edgar","filing":"0000899243-20-016183","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000089924320016183/doc4.xml","form_type":"4"}},{"id":3128896,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":36684,"kind":"person","name":"Miller-Rich Nancy","position":1,"cik":"0001735084","reported_name":"Miller-Rich Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2020-06-01T19:03:20.000Z","date":"2020-05-28","kind":"grant","acquired":true,"shares":2966,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"All of the options subject to the award shall vest and become exercisable on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2021 Annual Meeting of Stockholders."}],"balance_after":2966,"derivative":{"exercise_price":72.74,"expiration_date":"2030-05-28","underlying":"Common Stock","underlying_shares":2966},"source":{"system":"sec-edgar","filing":"0001104659-20-068534","document":"tm2021501d5_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465920068534/tm2021501d5_4.xml","form_type":"4"}},{"id":3128895,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":36684,"kind":"person","name":"Miller-Rich Nancy","position":1,"cik":"0001735084","reported_name":"Miller-Rich Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-06-01T19:03:20.000Z","date":"2020-05-28","kind":"grant","acquired":true,"shares":1595,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. All of the shares subject to the award shall vest on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2021 Annual Meeting of Stockholders."}],"balance_after":7538,"source":{"system":"sec-edgar","filing":"0001104659-20-068534","document":"tm2021501d5_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465920068534/tm2021501d5_4.xml","form_type":"4"}},{"id":3310615,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":36684,"kind":"person","name":"Miller-Rich Nancy","position":1,"cik":"0001735084","reported_name":"Miller-Rich Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-01-15T22:17:02.000Z","date":"2020-01-13","kind":"grant","acquired":true,"shares":24264,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Exercisable in equal annual installments over three years of continuous service to the Issuer after January 13, 2020."}],"balance_after":24264,"derivative":{"exercise_price":6.15,"expiration_date":"2030-01-12","underlying":"Common Stock","underlying_shares":24264},"source":{"system":"sec-edgar","filing":"0000899243-20-001261","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000089924320001261/doc4.xml","form_type":"4"}},{"id":3481150,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":36684,"kind":"person","name":"Miller-Rich Nancy","position":1,"cik":"0001735084","reported_name":"Miller-Rich Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2019-06-21T19:01:37.000Z","date":"2019-06-20","kind":"grant","acquired":true,"shares":2174,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"All of the options subject to the award shall vest and become exercisable on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2020 Annual Meeting of Stockholders."}],"balance_after":2174,"derivative":{"exercise_price":82.25,"expiration_date":"2029-06-20","underlying":"Common Stock","underlying_shares":2174},"source":{"system":"sec-edgar","filing":"0001144204-19-031958","document":"tv524024_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000114420419031958/tv524024_4.xml","form_type":"4"}},{"id":3481149,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":36684,"kind":"person","name":"Miller-Rich Nancy","position":1,"cik":"0001735084","reported_name":"Miller-Rich Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-21T19:01:37.000Z","date":"2019-06-20","kind":"grant","acquired":true,"shares":1570,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. All of the shares subject to the award shall vest on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2020 Annual Meeting of Stockholders."}],"balance_after":5943,"source":{"system":"sec-edgar","filing":"0001144204-19-031958","document":"tv524024_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000114420419031958/tv524024_4.xml","form_type":"4"}},{"id":3884852,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":36684,"kind":"person","name":"Miller-Rich Nancy","position":1,"cik":"0001735084","reported_name":"Miller-Rich Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2018-06-22T17:01:53.000Z","date":"2018-06-20","kind":"grant","acquired":true,"shares":7684,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/3rd of the shares subject to the award shall vest and become exercisable on each anniversary of the Vesting Commencement Date (or, if earlier in any given year, the day immediately preceding the date of the Issuer's Annual Meeting of Stockholders in such year).  The Vesting Commencement Date is April 24, 2018."}],"balance_after":7684,"derivative":{"exercise_price":85.12,"expiration_date":"2028-06-20","underlying":"Common Stock","underlying_shares":7684},"source":{"system":"sec-edgar","filing":"0001144204-18-035418","document":"tv496985_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000114420418035418/tv496985_4.xml","form_type":"4"}},{"id":3884851,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":36684,"kind":"person","name":"Miller-Rich Nancy","position":1,"cik":"0001735084","reported_name":"Miller-Rich Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-06-22T17:01:53.000Z","date":"2018-06-20","kind":"grant","acquired":true,"shares":4373,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. 1/3rd of the shares subject to the award shall vest on each anniversary of the Vesting Commencement Date (or, if earlier in any given year, the day immediately preceding the date of the Issuer's Annual Meeting of Stockholders in such year).  The Vesting Commencement Date is April 24, 2018."}],"balance_after":4373,"source":{"system":"sec-edgar","filing":"0001144204-18-035418","document":"tv496985_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000114420418035418/tv496985_4.xml","form_type":"4"}}]}